Loading...

Cancer Genetics

DB:1C8
Snowflake Description

Moderate growth potential and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1C8
DB
$13M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • Cancer Genetics has significant price volatility in the past 3 months.
1C8 Share Price and Events
7 Day Returns
20.2%
DB:1C8
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-70.5%
DB:1C8
-10.6%
DE Biotechs
-6.2%
DE Market
1C8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cancer Genetics (1C8) 20.2% 14.3% -28.9% -70.5% -90.6% -97.8%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • 1C8 underperformed the Biotechs industry which returned -10.6% over the past year.
  • 1C8 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
1C8
Industry
5yr Volatility vs Market

Value

 Is Cancer Genetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cancer Genetics. This is due to cash flow or dividend data being unavailable. The share price is €0.2367.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cancer Genetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cancer Genetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1C8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.75
NasdaqCM:CGIX Share Price ** NasdaqCM (2019-04-23) in USD $0.24
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cancer Genetics.

DB:1C8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CGIX Share Price ÷ EPS (both in USD)

= 0.24 ÷ -0.75

-0.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cancer Genetics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cancer Genetics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cancer Genetics's expected growth come at a high price?
Raw Data
DB:1C8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
69.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cancer Genetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cancer Genetics's assets?
Raw Data
DB:1C8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.25
NasdaqCM:CGIX Share Price * NasdaqCM (2019-04-23) in USD $0.24
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:1C8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CGIX Share Price ÷ Book Value per Share (both in USD)

= 0.24 ÷ 0.25

0.98x

* Primary Listing of Cancer Genetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cancer Genetics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cancer Genetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cancer Genetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cancer Genetics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cancer Genetics expected to grow at an attractive rate?
  • Cancer Genetics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Cancer Genetics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Cancer Genetics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1C8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1C8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 69.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1C8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1C8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 32
2022-12-31 16
2021-12-31 5
2020-12-31 -2
2019-12-31 47 -9 1
DB:1C8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 27 -13 -20
2018-09-30 28 -15 -25
2018-06-30 30 -14 -17
2018-03-31 30 -16 -16
2017-12-31 29 -14 -21
2017-09-30 29 -11 -16
2017-06-30 28 -13 -19
2017-03-31 28 -14 -20
2016-12-31 27 -18 -16
2016-09-30 25 -21 -19
2016-06-30 23 -19 -20
2016-03-31 20 -16 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cancer Genetics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Cancer Genetics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1C8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cancer Genetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1C8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.08 1.08 1.08 1.00
2022-12-31 0.54 0.54 0.54 1.00
2021-12-31 0.18 0.18 0.18 1.00
2020-12-31 -0.06 -0.06 -0.06 1.00
2019-12-31 -0.30 -0.30 -0.30 1.00
DB:1C8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.75
2018-09-30 -0.94
2018-06-30 -0.68
2018-03-31 -0.69
2017-12-31 -1.01
2017-09-30 -0.80
2017-06-30 -1.02
2017-03-31 -1.17
2016-12-31 -1.00
2016-09-30 -1.32
2016-06-30 -1.62
2016-03-31 -1.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cancer Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cancer Genetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cancer Genetics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cancer Genetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cancer Genetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cancer Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cancer Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cancer Genetics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cancer Genetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cancer Genetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1C8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 27.47 -20.37 24.45 2.49
2018-09-30 28.17 -24.51 28.76 3.76
2018-06-30 30.25 -16.62 28.12 4.04
2018-03-31 29.82 -15.76 26.79 4.36
2017-12-31 29.12 -20.88 24.88 4.79
2017-09-30 28.83 -15.76 20.08 4.24
2017-06-30 27.55 -18.87 19.19 4.85
2017-03-31 27.95 -20.13 19.53 5.55
2016-12-31 27.05 -15.80 20.70 5.97
2016-09-30 25.30 -18.74 23.47 4.85
2016-06-30 22.55 -20.21 23.45 5.06
2016-03-31 19.74 -21.16 22.66 4.64
2015-12-31 18.04 -20.18 21.14 4.38
2015-09-30 16.59 -19.64 18.44 5.86
2015-06-30 15.81 -19.23 17.89 5.45
2015-03-31 13.14 -18.44 16.96 5.30
2014-12-31 10.20 -16.64 16.33 4.62
2014-09-30 8.02 -13.99 13.39 3.90
2014-06-30 6.50 -12.26 10.96 2.94
2014-03-31 6.82 -17.22 9.47 2.30
2013-12-31 6.61 -12.37 7.96 2.19
2013-09-30 5.83 -13.89 6.91 1.94
2013-06-30 5.37 -10.51 6.65 2.01
2013-03-31 4.69 -3.23 6.24 2.08
2012-12-31 4.30 -6.67 5.55 2.11
2012-09-30 4.10 -5.67 5.83 2.18
2012-06-30 3.48 -7.49 5.67 2.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cancer Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cancer Genetics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cancer Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cancer Genetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cancer Genetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cancer Genetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cancer Genetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cancer Genetics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Cancer Genetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cancer Genetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cancer Genetics Company Filings, last reported 3 months ago.

DB:1C8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.80 12.35 0.16
2018-09-30 9.25 13.34 1.21
2018-06-30 17.28 10.32 1.60
2018-03-31 20.05 10.47 4.02
2017-12-31 26.77 11.03 9.54
2017-09-30 31.14 7.93 4.81
2017-06-30 18.63 7.79 6.17
2017-03-31 20.93 5.62 9.66
2016-12-31 25.62 5.14 9.50
2016-09-30 27.85 5.45 10.72
2016-06-30 29.16 5.96 10.55
2016-03-31 28.30 6.34 13.27
2015-12-31 33.02 6.37 19.46
2015-09-30 22.32 6.94 19.92
2015-06-30 26.81 7.26 23.74
2015-03-31 30.98 6.98 22.31
2014-12-31 34.56 6.92 25.55
2014-09-30 38.05 6.66 30.75
2014-06-30 40.51 6.39 37.42
2014-03-31 43.74 6.35 41.31
2013-12-31 45.58 6.38 49.46
2013-09-30 5.16 6.06 9.88
2013-06-30 -6.65 9.58 1.94
2013-03-31 -21.31 15.69 0.22
2012-12-31 -23.75 15.17 0.82
2012-09-30 -19.61 15.11 0.90
2012-06-30 -19.73 13.48 0.40
  • Cancer Genetics's level of debt (181.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (14% vs 181.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cancer Genetics has less than a year of cash runway based on current free cash flow.
  • Cancer Genetics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.2% each year.
X
Financial health checks
We assess Cancer Genetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cancer Genetics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cancer Genetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cancer Genetics dividends.
If you bought €2,000 of Cancer Genetics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cancer Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cancer Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1C8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1C8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cancer Genetics has not reported any payouts.
  • Unable to verify if Cancer Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cancer Genetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cancer Genetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cancer Genetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cancer Genetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cancer Genetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cancer Genetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jay Roberts
COMPENSATION $404,617
AGE 59
TENURE AS CEO 1.2 years
CEO Bio

Mr. John A. Roberts, also known as Jay, MBA has been Chief Executive Officer and President of Cancer Genetics, Inc., since April 30, 2018. Mr. Roberts has been Chief Operating Officer of Cancer Genetics, Inc. since July 11, 2016. He served as Interim Chief Executive Officer of Cancer Genetics, Inc. from February 2, 2018 to April 30, 2018. Mr. Roberts served as Executive Vice President of Finance at Cancer Genetics, Inc. from July 11, 2016 to February 5, 2018 and served as its Principal Financial Officer since February 3, 2017 until February 5, 2018 and also its Secretary since July 11, 2016 until February 5, 2018. Mr. Roberts served as a Partner of Tatum CFO Partners, LLP. Mr. Roberts served as the Chief Financial and Administrative Officer at Advantedge Healthcare Solutions, Inc. from August 1, 2011 to July 31, 2015. Mr. Roberts serves as a Secretary of Radiate Research Inc. and served as its President until May 2, 2005. He has over 22 years of comprehensive experience in corporate finance, with an accomplished track record as a senior executive focused on healthcare information technology. He has served as a recognized thought leader and expert panelist for numerous publications and programs related to corporate finance and mergers and acquisitions in the healthcare industry. Mr. Roberts served as Principal Accounting Officer of InfoLogix, Inc. and served as its Chief Financial Officer and Treasurer since September 2006 until July 2011. He served as Secretary of InfoLogix, Inc. since November 2006 until July 2011. In his Chief Financial Officer and senior executive roles with firms such as PharMerica and the Center for Health Information, Mr. Roberts has led many successful corporate development projects adding key assets via acquisition and strategic partnering. Prior to his immersion in the health care vertical, Mr. Roberts founded a successful corporate financial advisory and private investment banking firm offering private placement, merger and acquisition, strategic planning, financial and legal due diligence and turn-around consulting. Mr. Roberts served as Acting Chief Financial Officer and Secretary of Clarient, Inc. from February 2006 to June 19, 2006 and also served as its Principal Accounting Officer until June 19, 2006. He served as Chief Financial Officer and Secretary of Daou Systems, Inc. from December 2003 to 2006. He was employed at VirMedica and served as the Chief Financial Officer for VirMedica, Inc. Prior to joining Daou Systems, he served as the Vice President of Business Development for MEDecision, Inc. from 2001 to 2002. Prior to that, Mr. Roberts served as Senior Vice President of Corporate Development and Chief Financial Officer of HealthOnline, Inc. from 1999 to 2001. As President for Roberts, Hackett & Company, Inc., he raised a $25 million private equity fund, completed several acquisitions and led its strategy consulting group. He is a Member of Tatum Partners. He serves as Director of Cancer Genetics, Inc. He is a member of the Board of Directors and Chairman Elect for the Drug Information Association, a global neutral forum enabling drug developers and regulators access to education and collaboration. He served as a Director of Radiate Research Inc. and Drug Information Association. He served as director for the United Way and New Beginnings, Inc. Mr. Roberts holds a Bachelor of Science and a Master’s degree in Business Administration from the University of Maine.

CEO Compensation
  • Jay's compensation has increased whilst company is loss making.
  • Jay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cancer Genetics management team in years:

1
Average Tenure
59
Average Age
  • The average tenure for the Cancer Genetics management team is less than 2 years, this suggests a new team.
Management Team

Jay Roberts

TITLE
President
COMPENSATION
$405K
AGE
59
TENURE
1.2 yrs

Michael Miles

TITLE
Chief Financial Officer
TENURE
0.4 yrs

Mike McCartney

TITLE
Chief Commercial Officer
TENURE
0.8 yrs

William Finger

TITLE
Executive Vice President of Precision Medicine & Biopharma Solutions
TENURE
0.3 yrs

Ralf Brandt

TITLE
President of Discovery & Early Development Services
AGE
55
TENURE
1.7 yrs

Jane El Naggar

TITLE
Vice President of Research & Development
COMPENSATION
$303K
AGE
59
TENURE
7.8 yrs

Lan Wang

TITLE
Medical Director of New Jersey Reference Laboratory & Consultant
Board of Directors Tenure

Average tenure and age of the Cancer Genetics board of directors in years:

6.3
Average Tenure
73
Average Age
  • The tenure for the Cancer Genetics board of directors is about average.
Board of Directors

John Pappajohn

TITLE
Chairman of the Board
COMPENSATION
$274K
AGE
89
TENURE
5.3 yrs

Jay Roberts

TITLE
President
COMPENSATION
$405K
AGE
59

Edmund Cannon

TITLE
Independent Director
COMPENSATION
$74K
AGE
73
TENURE
14.3 yrs

Frank Prendergast

TITLE
Independent Director
COMPENSATION
$74K
AGE
73
TENURE
7.3 yrs

Geoffrey Harris

TITLE
Independent Director
COMPENSATION
$79K
AGE
56
TENURE
4.3 yrs

Raju S. Chaganti

TITLE
Founder & Director
COMPENSATION
$74K
AGE
85
TENURE
20 yrs

Vundavalli Murty

TITLE
Member of Scientific Advisory Board

Timothy Chan

TITLE
Member of Scientific Advisory Board

Hans-Guido Wendel

TITLE
Member of Scientific Advisory Board

Michael Welsh

TITLE
Independent Director
COMPENSATION
$71K
AGE
69
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Cancer Genetics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Feb 19 Buy John Roberts Individual 31. Jan 19 31. Jan 19 185,436 €0.20 €37,234
01. Feb 19 Buy Michael Miles Individual 31. Jan 19 31. Jan 19 150,000 €0.20 €30,119
01. Feb 19 Buy Edmund Cannon Individual 31. Jan 19 31. Jan 19 43,479 €0.20 €8,730
01. Feb 19 Buy John Pappajohn Individual 31. Jan 19 31. Jan 19 1,000,000 €0.20 €200,790
16. Jan 19 Buy Geoffrey Harris Individual 14. Jan 19 14. Jan 19 100,000 €0.20 €19,604
16. Jan 19 Buy John Pappajohn Individual 14. Jan 19 14. Jan 19 1,000,000 €0.20 €196,043
16. Jan 19 Buy John Roberts Individual 14. Jan 19 14. Jan 19 100,000 €0.20 €19,604
X
Management checks
We assess Cancer Genetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cancer Genetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company’s biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company’s discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Details
Name: Cancer Genetics, Inc.
1C8
Exchange: DB
Founded: 1999
$11,505,608
56,276,222
Website: http://www.cancergenetics.com
Address: Cancer Genetics, Inc.
201 Route 17 North,
2nd Floor,
Rutherford,
New Jersey, 07070,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CGIX Common Stock Nasdaq Capital Market US USD 05. Apr 2013
DB 1C8 Common Stock Deutsche Boerse AG DE EUR 05. Apr 2013
Number of employees
Current staff
Staff numbers
159
Cancer Genetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:51
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/04/16
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.